Trial Profile
A retrospective study to evaluate de novo use of Everolimus in late onset cytomegalovirus primary diseases after withdrawal of antiviral prophylaxis in kidney transplant patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 05 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress